Mirae Asset Global Etfs Holdings Ltd. Cardiff Oncology, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.4 Billion
- Q1 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 34,319 shares of CRDF stock, worth $117,027. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,319
Previous 22,822
50.38%
Holding current value
$117,027
Previous $99,000
8.08%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CRDF
# of Institutions
124Shares Held
29MCall Options Held
900KPut Options Held
234K-
Commodore Capital LP New York, NY5.38MShares$18.4 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.12MShares$10.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$8.96 Million0.0% of portfolio
-
Blair William & CO Chicago, IL1.75MShares$5.97 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.45MShares$4.93 Million0.01% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $148M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...